Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19

NCT05620160 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1359

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild to Moderate COVID-19

Interventions

DRUG: RAY1216
DRUG: Placebo

Sponsor

Guangdong Raynovent Biotech Co., Ltd